RevMab

anti-Galectin-9 (human), Rabbit Monoclonal (RM499)

CHF 459.00
In stock
REV-31-1391-00-R100100 µlCHF 459.00
More Information
Product Details
Synonyms Gal-9; Ecalectin; Tumor Antigen HOM-HD-21; TIM-3 Ligand; T Cell Immunoglobulin and Mucin Domain-containing Protein 3 Ligand
Product Type Recombinant Antibody
Properties
Clone RM499
Isotype Rabbit IgG
Source/Host Rabbit
Immunogen/Antigen A peptide corresponding to the N-terminus of human Galectin-9 (Gal-9).
Application

Immunohistochemistry (IHC): 1:100-1:200 dilution
Western Blot (WB): 1:250-1:1000 dilution

Crossreactivity Human
Specificity

This antibody reacts to human Galectin-9.

Purity Protein A purified.
Purity Detail Protein A affinity purified from an animal origin-free culture supernatant.
Concentration N/A
Formulation Liquid. 50% Glycerol/PBS with 1% BSA and 0.09% sodium azide.
Isotype Negative Control

Rabbit IgG

Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

Accession Number O00182
Declaration Manufactured by RevMab Biosciences.
Shipping and Handling
Shipping BLUE ICE
Long Term Storage -20°C
Handling Advice Avoid freeze/thaw cycles.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Description

Galectin-9 (Gal-9), a β-galactoside-binding protein, primarily plays an immunosuppressive role in the tumor microenvironment, via binding with several cell surface receptors expressed on immune cells. Although Gal-9 was initially identified as a ligand for T-cell immunoglobulin and mucin domain–containing molecule 3 (TIM-3) in the induction of T-cell death, it also binds to other immunoregulatory receptors. For instance, Gal-9 binding to the innate receptor dectin-1 promotes M2 polarization of macrophages that suppresses antitumor immune responses. Gal-9 has also been shown to promote the differentiation of regulatory T cells (Tregs) through interaction with cluster of differentiation 44 (CD44) and drive the expansion of Tregs through binding with death receptor 3. The aberrantly high expression of Gal-9 in a range of cancers suggests that Gal-9 could be significant both as a biomarker and a therapeutic target.

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.